McCann FitzGerald advises AbbVie on its acquisition of Allergan
McCann FitzGerald is very pleased to be advising AbbVie on its acquisition of Allergan in a cash and stock transaction with a transaction equity value of approximately $63 billion.
McCann FitzGerald is very pleased to be advising AbbVie on its acquisition of Allergan in a cash and stock transaction with a transaction equity value of approximately $63 billion.
Filter by:
Are you looking for someone or
something in particular?
Select how you would like to share using the options below